A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Multiple Oral TAK-648 Doses in Healthy Japanese Subjects and non Japanese Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2016
At a glance
- Drugs TAK 648 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Takeda
- 12 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 09 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015 as per ClinicalTrials.gov record.